Newsletter Subscription

Enter Name and Email

27 September 2013 - Invited lecture at the Karolinska Institute, Stockholm

Adrian Newman-Tancredi, PhD, DSc, gave an invited lecture on Wednesday 25 September 2013 at the Neuroscience Dept. of the prestigious Karolinska Institute medical university. The lecture was entitled: "The novel pharmacology of antipsychotics: how recent advances point to a key role for serotonin 5-HT1A receptors" and described neurochemical and molecular evidence indicating that this receptor profoundly influences cognition and negative symptoms in schizophrenia.

In particular, Adrian focused on the perspectives for "personalised medicine" in which novel drugs exhibiting "biased agonism" can target specific subpopulations of 5-HT1A receptors in relevant brain regions. Such drugs could represent promising treatments for patients that possess certain risk genes such as the 5-HT1A promoter single nucleotide polymorphims (SNP) rs6295, which is associated with treatment resistance to antipsychotics, as concerns negative symptoms. This is likely mediated by hypofunction of cortical 5-HT1A receptors and could be treated using cortically-targeted biased agonists such as the one in-licensed by Neurolixis, a biotechnology company of which Adrian is Chief Scientific Officer (see press release).

Adrian's visit to the Karolinska Institute was hosted by Prof. Sven Ove Ögren, an expert in the mechanism of action of antipsychotics and antidepressants.

If you would like to know more about Adrian's lectures and/or his ongoing engagement with academic centres of excellence, Contact.